Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-25-051095
Filing Date
2025-11-10
Accepted
2025-11-10 16:33:17
Documents
101
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q adc-20250930.htm   iXBRL 10-Q 1416531
2 EX-31.1 ex311-ceocertification302q.htm EX-31.1 9772
3 EX-31.2 ex312-cfocertification302q.htm EX-31.2 9794
4 EX-32.1 ex321-ceocertification906q.htm EX-32.1 4768
5 EX-32.2 ex322-cfocertification906q.htm EX-32.2 4776
11 adc-20250930_g1.jpg GRAPHIC 9084
  Complete submission text file 0001628280-25-051095.txt   7820345

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT adc-20250930.xsd EX-101.SCH 58443
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT adc-20250930_cal.xml EX-101.CAL 88983
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT adc-20250930_def.xml EX-101.DEF 263378
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT adc-20250930_lab.xml EX-101.LAB 669746
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT adc-20250930_pre.xml EX-101.PRE 516880
104 EXTRACTED XBRL INSTANCE DOCUMENT adc-20250930_htm.xml XML 1078648
Mailing Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066
Business Address BIOPOLE ROUTE DE LA CORNICHE 3B EPALINGES V8 1066 41 21 653 02 00
ADC Therapeutics SA (Filer) CIK: 0001771910 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39071 | Film No.: 251466815
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)